Compare Biogen Inc (BIIB) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs SoFi Technologies Inc — how do they compare? Biogen Inc trades at $206.8 (market cap $30.13B), while SoFi Technologies Inc trades at $17.81 (market cap $23.22B). The key difference: Biogen Inc is the larger of the two by market cap, and Biogen Inc is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | SOFI | |
|---|---|---|
Market Cap | $30.13B | $23.22B |
Sector | Health | Financials |
52-Week High | $216.63 | $32.21 |
52-Week Low | $128.93 | $15.15 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
SOFI trades at $18.12, down 1.41% today, with a bullish technical signal and recent earnings beats. Revenue grew to $3.61B in 2025, with a net income margin of 14.78%. The stock is supported by strong member growth and a consensus price target of $19.50, though negative operating cash flow and high valuation ratios present challenges.
Outlook is cautiously optimistic with growth potential from digital banking expansion, but risks include persistent negative cash flow, competitive pressures, and sensitivity to interest rate changes. Analyst sentiment is mixed, with 33% buy ratings highlighting upside, while high P/E of 36.69 warrants caution for value-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
